qRT-PCR analysis confirmed that BCR-ABL+ LSC contributed to engraftment in all experimental arms, and BCR-ABL mRNA levels were reduced in CD45+ cells obtained from the BM of mice receiving CML cells treated with the combination of LDE225 + nilotinib, compared with untreated or single agent LDE225 (Fig. 6E). The gene discussed is PTPRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.